89bio, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
89bio, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q2 2024.
  • 89bio, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$48M, a 24.9% decline year-over-year.
  • 89bio, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$175M, a 47.2% decline year-over-year.
  • 89bio, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$142M, a 39.4% decline from 2022.
  • 89bio, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$102M, a 13.2% decline from 2021.
  • 89bio, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$90.1M, a 82.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$175M -$48M -$9.58M -24.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 -$165M -$51.7M -$22.8M -79.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-05
Q4 2023 -$142M -$40.2M -$15.6M -63.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$127M -$34.7M -$7.92M -29.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$119M -$38.4M -$13.3M -53.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$105M -$28.8M -$3.27M -12.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-05
Q4 2022 -$102M -$24.6M +$1.69M +6.41% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$104M -$26.8M +$1.52M +5.38% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$105M -$25.1M -$4.33M -20.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$101M -$25.6M -$10.8M -72.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$90.1M -$26.3M -$13.7M -109% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-01
Q3 2021 -$76.4M -$28.3M -$13.7M -94% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$62.7M -$20.7M -$8.95M -76.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$53.7M -$14.8M -$4.24M -40.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$49.5M -$12.6M +$6.7M +34.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$56.2M -$14.6M +$4.12M +22% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$60.3M -$11.8M +$2.75M +19% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$63.1M -$10.5M -$6.11M -138% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$57M -$19.3M -$14.6M -316% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-18
Q3 2019 -$42.3M -$18.7M -$14.6M -350% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$27.8M -$14.5M -$7.15M -97% Mar 31, 2019 Jun 30, 2019 10-Q 2019-12-18
Q1 2019 -$20.6M -$4.44M -$4.44M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-13
Q4 2018 -$16.2M -$4.64M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-18
Q3 2018 -$4.17M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-18
Q2 2018 -$7.37M Mar 31, 2018 Jun 30, 2018 10-Q 2019-12-18
Q1 2018 $0 Jan 19, 2018 Mar 30, 2018 10-Q 2019-12-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.